ClinicalTrials.gg
Not yet recruitingNCT07162740ILR-CNAUpdated Sep 9, 2025

Implantable Loop Recorder and Cardioneuroblation

An observational study in Reflex Syncope, sponsored by Istituto Auxologico Italiano. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by Istituto Auxologico Italiano · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 18 Years
Sex
All
01

Study summary

The study aims to determine which method of vagal ganglia ablation is most effective in preventing recurrences of reflex asystole syncope. Currently, some centers perform ablation only in the right atrium, others in both atria (biatrial). There are no comparative studies between the two procedures

Read the detailed description

Cardioneuroablation (CNA) therapy for reflex asystole syncope is becoming increasingly popular. The best method of CNA is debated, with no studies comparing the syncopal recurrence rates of right atrium ablation versus bi-atrial ablation. Evaluating the clinical efficacy of CNA is challenging due to symptom variability, intermittent presentation, complex pathophysiology, and different treatment options. The difficulty of obtaining precise follow-up data in patients with intermittent symptoms is well known. With ILR, more objective tracking can be achieved.

The aim of the study is to verify the efficacy of CNA on the reduction of the asystole reflex documented by continuous monitoring by ILR in patients undergoing right atrial ablation compared to bi-atrial ablation

02

Conditions studied

  • Reflex Syncope

Keywords

  • Syncope
  • reflex syncope
  • implantable loop recorder
  • Vagal ganglia ablation
  • Cardioneuroablation
  • Asystole
03

In context

Syncope, Vasovagal

88 studies on the registry are indexed under Syncope, Vasovagal; 28 are open to participants now.

This study's planned enrollment of 50 is below the median of 140 across 29 observational studies indexed under Syncope, Vasovagal.

Browse Syncope, Vasovagal studies →

Lead sponsor

Istituto Auxologico Italiano is the lead sponsor of 202 studies on the registry; 68 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Established asystolic reflex syncope

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 60 years
  • Clinical diagnosis of reflex syncope as per class I criteria of the ESC guidelines
  • History of recurrent severe syncopes (≥2 in the last year or ≥3 in the last 2 years), significantly affecting the quality of life, nonresponding to lifestyle measures.
  • Documentation by means of prolonged monitoring of an asystolic pause >6 sec or of an asystolic syncope >3 sec and/or an asystolic syncope induced during tilt testing (Vasis 2B form).

Exclusion criteria

Exclusion Criteria:

  • Intrinsic sinus dysfunction or atrioventricular node disease.
  • Constitutional hypotension and orthostatic intolerance syndromes
  • Overt structural heart disease
  • Alternative diagnoses of syncope
  • Pregnancy or breastfeeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Right atrial ablation group

    Procedure: Right atrial ablation

  • Bi-atrial ablation group

    Procedure: Bi-atrial ablation

Interventions

  • ProcedureRight atrial ablation

    Eligible patients receive the implantation of a LuxDx® ILR and are monitored for one month by means of the Latitude Clarity data management system of the device. The usual practice of the centres is unchanged. According to their usual practice, the centre is assigned to right atrial ablation. The patients receive a right atrial procedure accordingly. As per pragmatic design, cross-over are permitted according to investigator judgment. The ablation methods and techniques are left to investigator's decision. They are reported in the CRF.

  • ProcedureBi-atrial ablation

    Eligible patients receive the implantation of a LuxDx® ILR and are monitored for one month by means of the Latitude Clarity data management system of the device. The usual practice of the centres is unchanged. According to their usual practice, the centre is assigned to bi-atrial ablation. The patients receive a bi-atrial procedure accordingly. As per pragmatic design, cross-over are permitted according to investigator judgment. The ablation methods and techniques are left to investigator's decision. They are reported in the CRF.

06

What researchers measure

Primary outcomes

  1. Mounthly frequency of asystolic episodes >3 sec

    Frequency of asystolic episodes \>3 sec per month detected through ILR monitoring before and after ablation.

    Time frame: through study completion, an average of 1 year

  2. Freedom from ablation-related complications

    Freedom from ablation-related complications and from pacemaker implantation during the follow-up period;

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Burden of syncopal episodes

    Comparison betwen the mounthly burden of syncopal episodes before and after ablation;

    Time frame: through study completion, an average of 1 year

  2. heart rate (HR) and heart rate variability (HRV)

    Pattern of heart rate (HR) and heart rate variability (HRV) detected by ILR before andafter ablation.

    Time frame: through study completion, an average of 1 year

  3. Time to first asystolic and syncope recurrence

    Tme to first asystolic pause \>3 sec e and to first syncope recurrence

    Time frame: through study completion, an average of 1 year

07

Study locations

1 site
08

References and documents

Publications

  • Kulakowski P, Baran J, Sikorska A, Krynski T, Niedzwiedz M, Soszynska M, Piotrowski R. Cardioneuroablation for reflex asystolic syncope: Mid-term safety, efficacy, and patient's acceptance. Heart Rhythm. 2024 Mar;21(3):282-291. doi: 10.1016/j.hrthm.2023.11.022. Epub 2023 Nov 29. PubMed 38036236 ↗
  • Calo L, Rebecchi M, De Ruvo E, Giamundo D, Sette A, Tomaino M, Hunteruber M, Bottoni N, Iori M, Donateo P, Maggi R, Del Rosso A, Rafanelli M, Russo V, Strano S, Brignole M. Right atrial cardioneuroablation of asystolic reflex syncope. Heart Rhythm. 2025 Oct;22(10):e951-e958. doi: 10.1016/j.hrthm.2025.05.038. Epub 2025 May 22. PubMed 40412604 ↗
  • Aksu T, Brignole M, Calo L, Debruyne P, Di Biase L, Deharo JC, Fanciulli A, Fedorowski A, Kulakowski P, Morillo C, Moya A, Piotrowski R, Stec S, Sutton R, van Dijk JG, Wichterle D, Tse HF, Yao Y, Sheldon RS, Vaseghi M, Pachon JC, Scanavacca M, Meyer C, Amin R, Gupta D, Magnano M, Malik V, Schauerte P, Shen WK, Acosta JCZ. Cardioneuroablation for the treatment of reflex syncope and functional bradyarrhythmias: A Scientific Statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS) and the Latin American Heart Rhythm Society (LAHRS). Europace. 2024 Aug 3;26(8):euae206. doi: 10.1093/europace/euae206. PubMed 39082698 ↗

Individual participant data

Plan to share: Yes — After 6 months from the publication of the study upon reasonable request

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07162740
Responsible party
Sponsor
First posted
Sep 9, 2025
Start date
Oct 1, 2025 (estimated)
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Sep 9, 2025

Study contacts

Michele Brignole, Cardiologist
Contact
mbrignole@outlook.it
+393204391422
Luca Grappiolo
Contact
luca.grappiolo@auxologico.it
+3902619111 ext. 2894

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion